Following a robust earnings season, the week ahead brings another wave of financial reports from major companies in the S&P 500, including six notable stocks from a prominent investment portfolio. As of the previous week, earnings reports indicated a strong performance among the companies that have already shared their results; approximately 75% exceeded earnings-per-share expectations, while 65% reported positive revenue surprises. By the end of the week, more than half of the S&P 500 constituents are expected to have disclosed their fourth-quarter earnings.
Attention will also turn to the Labor Department’s monthly jobs report for January, set to release on Friday. This report is particularly crucial for investors, reflecting the health of a consumer-centric economy where around two-thirds of GDP is dependent on private consumption. Investors will examine job additions, the unemployment rate, and wage growth as indicators of consumer strength. Economists anticipate the addition of 75,000 jobs, an unchanged unemployment rate of 4.4%, and a 0.3% monthly rise in average hourly earnings, as reported by FactSet.
In addition to the jobs report, various economic indicators will be released, including the Job Openings and Labor Turnover Survey (JOLTS) on Tuesday and the ADP employment survey on Wednesday, though these are considered less critical to the overall economic picture. Manufacturing PMI data will be unveiled on Monday, followed by services PMI data on Wednesday, hinting that the manufacturing sector may still be in contraction while services could show continued expansion.
Focusing on the six portfolio companies reporting this week:
-
Eaton Corporation: Recently, Eaton announced plans to spin off its Mobility Group, a strategic move aimed at bolstering its Electrical and Aerospace segments. Despite mixed results in previous quarters, analysts are optimistic about future growth, forecasting revenues of $7.1 billion and earnings per share of $3.29.
-
Eli Lilly: Investors will be keenly observing the sales performance of Eli Lilly’s GLP-1 medications, Mounjaro and Zepbound, with street expectations set at over $10 billion for the quarter. Insights into orforglipron, a potential FDA-approved oral GLP-1 drug, as well as management’s revenue forecast for 2026 in light of changing pricing dynamics, will be vital. Overall revenue is projected at $17.93 billion, with earnings expected at $6.93 per share.
-
Alphabet Inc.: Increased scrutiny awaits the search and cloud powerhouse, particularly regarding its heavy investments in artificial intelligence. The performance of its new Gemini 3 chatbot could bolster growth indicators, particularly in the realms of cloud services and search results. Analysts predict revenues of $95.23 billion with earnings of $2.63 per share.
-
Bristol Myers Squibb: This pharmaceutical giant will face challenges given the loss of exclusivity for several key drugs. Investors will be focusing on the performance of its growth portfolio, which includes promising drugs such as Opdivo and Reblozyl. Estimated revenues are forecasted to reach $12.28 billion, with earnings at $1.12 per share.
-
Linde plc: Linde’s forthcoming earnings report will be crucial in assessing whether recent gains in stock value are justifiable, particularly against a backdrop of subdued industrial activity. Analysts expect revenues of $8.64 billion and earnings of $4.18 per share, with a focus on discussions surrounding long-term growth drivers like decarbonization and its role in the space industry.
-
Amazon.com, Inc.: All eyes will be on Amazon Web Services’ performance, regarded as the company’s primary profit engine, especially following reports from smaller competitors. Investors will anticipate insights from CEO Andy Jassy on AI computing demand and updates concerning its physical retail strategy alongside the advertising business. Forecasted revenues reach $211.32 billion with earnings anticipated at $1.97 per share.
As the week unfolds, a variety of earnings reports will be released, including those from notable companies such as Walt Disney Co., Pfizer, and Amazon, prompting significant market reactions based on the financial health and forecasts provided by these industry leaders.
